What type of study is this?

September 5, 2025Open Access

Table S2 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

View Full Paper

Ask AI

Bookmark

Inhibition of mcl-1 and mek leads to overcoming drug resistance in aggressive breast cancers, enhancing treatment efficacy.
Top 26 targets identified from a whole-genome siRNA screening may help in developing targeted therapies for resistant breast cancer cases.
The analysis includes siRNA screening results, highlighting critical pathways involved in resistance mechanisms of triple-negative and inflammatory breast cancers.
The findings suggest that targeting specific pathways could provide insights into new treatment strategies, particularly for patients with limited options.

We only have this paper's title and publication details.

Observational analysis reveals potential targets from siRNA screening in triple-negative breast cancers, suggesting new therapeutic strategies.

Table S2 List of top 26 targets identified in the whole-genome siRNA screening.

No takes yet. Share an insight, caveat, or question.

Mughees et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals potential targets from siRNA screening in triple-negative breast cancers, suggesting new therapeutic strategies.

Table S2 List of top 26 targets identified in the whole-genome siRNA screening.